← Back to Search
Safety, Tolerability And Pharmacokinetics Of The Fibroblast Growth Factor Receptor Inhibitor AZD4547 In Japanese Patients With Advanced Solid Tumours: A Phase I Study
H. Saka, C. Kitagawa, Y. Kogure, Y. Takahashi, K. Fujikawa, T. Sagawa, S. Iwasa, N. Takahashi, Taro Fukao, C. Tchinou, D. Landers, Y. Yamada
Published 2016 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
SummaryBackground AZD4547 is a potent, oral, highly selective fibroblast growth factor receptor (FGFR) inhibitor in clinical development for treating tumours with a range of FGFR aberrations, including FGFR mutations, amplifications and fusions. Methods This open-label, Phase I, multicentre study (NCT01213160) evaluated the safety, pharmacokinetics, and preliminary antitumour efficacy (RECIST v1.1) of AZD4547 monotherapy in Japanese patients with advanced solid tumours. Part A was a dose-escalation part; Part B was a dose-expansion part in patients with FGFR-amplified tumours, confirmed by fluorescence in situ hybridization. Results Thirty patients enrolled in Part A (dose range: 40 mg twice daily [bid] to 120 mg bid; 160 mg once daily [qd]), four in Part B (80 mg bid). No dose-limiting toxicities were observed and maximum tolerated dose was not determined. Most common adverse events (AEs; any grade) were: dysgeusia (50% of patients); stomatitis (41%); diarrhoea (38%); hyperphosphataemia (38%); dry mouth (35%). Common grade ≥3 AEs were nausea (12% of patients) and neutropenia (9%). No complete or partial responses were observed: 21/30 patients had stable disease ≥4 weeks in Part A, and 1/4 patients had stable disease ≥10 weeks in Part B. Following single and multiple dosing, absorption rate appeared moderate; peak plasma concentrations generally occurred 3–4 h post-dose, then declined biphasically with terminal half-life ~30 h. Steady state was reached by day 8. Compared with single dosing, plasma concentrations were, on average, 2.4- and 3.3- to 5.4-fold higher after qd and bid dosing, respectively. Conclusions AZD4547 was well tolerated in Japanese patients, with best response of stable disease ≥4 weeks.
This paper references
FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.
R. Jones (2016)
A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.
H. Arkenau (2014)
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
: current progress , unresolved questions and future directions
O Casanovas (2005)
2016) BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer
T Powles (2016)
A phase 2 trial of ponatinib in Philadelphia chromosomepositive leukemias
JE Cortes (2013)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer.
T. Powles (2016)
Genomic characterization and targeted therapeutics in squamous cell lung cancer
P Hammerman (2011)
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
J. Taylor (2009)
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
I. Weinstein (2006)
Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor
Alan P. Brown (2005)
A phase 2 study of BGJ 398 in patients ( pts ) with advanced or metastatic FGFR - altered cholangiocarcinoma ( CCA ) who failed or are intolerant to platinum - based chemotherapy
MM Javle (2016)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
J. Tabernero (2015)
Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.
L. Nogova (2014)
Phase I dose-escalation study of JNJ42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
J Tabernero (2015)
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer 8:59–60
JD Robertson (2009)
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
E. Smyth (2015)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
M. Reck (2014)
A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.
Y. Bang (2015)
Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
L V Sequist (2014)
A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
TT Batchelor (2008)
Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial
WT van Der Graaf (2012)
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
F. Courjal (1997)
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
A. Du Bois (2016)
AZD4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells
TJ Yao (2015)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
W. Graaf (2012)
AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells
Ting-jing Yao (2015)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
C. Sternberg (2013)
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)
B. Escudier (2005)
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
B. Escudier (2009)
Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer
K. Holzmann (2012)
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
M. Schlumberger (2015)
Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
Jingchuan Zhang (2012)
BekaiiSaab TS (2016) A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy
MM Javle (2016)
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
D. Cappellen (1999)
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
J. Chang (2015)
Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .
F. André (2013)
Sorafenib in advanced hepatocellular carcinoma.
G. Spinzi (2008)
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
N. Vasudev (2014)
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
P. Gavine (2012)
Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
D. Hyman (2016)
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
J. Robertson (2009)
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
T. Helsten (2015)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A. Grothey (2013)
Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind
W T Van Der Graaf (2012)
Shortening the timeline of pediatric phase I trials: the rolling six design.
J. Skolnik (2008)
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
R. Motzer (2009)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
A. Dutt (2008)
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
J. Ledermann (2013)
FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
L. Xie (2013)
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
S. Sleijfer (2009)
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
A. Pearson (2016)
Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?
J. Lewin (2015)
Cellular signaling by fibroblast growth factor receptors.
V. P. Eswarakumar (2005)
A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations.
A. Siefker-Radtke (2016)
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
S. Kopetz (2010)
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
S. Pal (2018)
Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
B. Escudier (2014)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng (2009)
Functions and regulations of fibroblast growth factor signaling during embryonic development.
B. Thisse (2005)
A Phase III randomized study comparing the efficacy of cediranib asmonotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients
T Batchelor (2010)
Anti - angiogenic therapy for
NS Vasudev (2014)
Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically Invest New Drugs
LV Sequist (2014)
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors
F. André (2013)
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
C. Sternberg (2010)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
O. Casanovas (2005)
Genomic characterization and targeted therapeutics in squamous cell lung cancer. 14th World Conference on Lung Cancer
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
J. E. Cortes (2013)
2016) Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
A du Bois (2016)
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
M. Javle (2016)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled
A Grothey (2013)
Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
L. Sequist (2014)
Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.
S. Pal (2016)
Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
T. Batchelor (2008)
This paper is referenced by
Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
Nikki Phanhthilath (2020)
Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors
Alan Jiang (2018)
First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
Takafumi Koyama (2019)
Upregulation of Fibroblast Growth Factors Caused by Heart and Neural Crest Derivatives Expressed 2 Suppression in Endometriotic Cells: A Possible Therapeutic Target in Endometriosis
Nao Kato (2019)
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
S. Taurin (2018)
Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer
Li-ping Shan (2019)
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Y. Chae (2020)
Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14
Tomohisa Okuno (2018)
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K. Papadopoulos (2017)
FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
A. Raja (2019)
Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors
Y. Zhang (2017)
HGFR and FGR2: Their Roles in Progression and Metastasis of Esophageal Cancer
R. Kumar (2018)
Targeted and novel therapy in advanced gastric cancer
Julie H. Selim (2019)
Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma
Alok R. Khandelwal (2019)
Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
Jeffrey Ahn (2019)
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
F. Facchinetti (2019)
Recent developments and advances of FGFR as a potential target in cancer.
Wen-jun Xue (2018)
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
M. Fisher (2020)
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer
E. Rijavec (2017)
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
T. Yamamoto (2020)
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
A. Mahipal (2019)